基本信息
views: 106
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Research Focus
The focus of Dr. Lowenstein's research program is to discover the cellular, molecular, and mathematical basis underlying the growth patterns of malignant brain tumors, the molecular and cellular mechanisms that mediate tumor immune escape and the interactions between cancer cells with the tumor microenvironment, in both experimental models and in human patients suffering from malignant brain tumors. His group has shown that galectin-1 knockdown in cancer cells causes the eradication of intracranial glioma in RAG1-/- mice lacking mature B- and T-cells by sensitizing tumor cells to NK cytotoxicity. Conversely, in NK cell depleted RAG1-/- mice, and severely immunocompromised NOD-scid IL2Rg null mice, galectin-1 deficient glioma cells progress killing the host with 100% efficiency. C57BL/6J mice with intact B- and T-cells enable galectin-1 deficient glioma growth only when NK cells are depleted. The data indicate that adaptive immunity is not required for galectin-1 deficient glioma rejection. Investigation is underway into therapeutic galectin-1 suppression to improve outcomes in patient survival by heightening NK immune surveillance.
The focus of Dr. Lowenstein's research program is to discover the cellular, molecular, and mathematical basis underlying the growth patterns of malignant brain tumors, the molecular and cellular mechanisms that mediate tumor immune escape and the interactions between cancer cells with the tumor microenvironment, in both experimental models and in human patients suffering from malignant brain tumors. His group has shown that galectin-1 knockdown in cancer cells causes the eradication of intracranial glioma in RAG1-/- mice lacking mature B- and T-cells by sensitizing tumor cells to NK cytotoxicity. Conversely, in NK cell depleted RAG1-/- mice, and severely immunocompromised NOD-scid IL2Rg null mice, galectin-1 deficient glioma cells progress killing the host with 100% efficiency. C57BL/6J mice with intact B- and T-cells enable galectin-1 deficient glioma growth only when NK cells are depleted. The data indicate that adaptive immunity is not required for galectin-1 deficient glioma rejection. Investigation is underway into therapeutic galectin-1 suppression to improve outcomes in patient survival by heightening NK immune surveillance.
Research Interests
Papers共 455 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
crossref(2024)
crossref(2024)
crossref(2024)
Molecular Therapyno. 5 (2024): 1187-1189
Syed M Faisal, Jarred E Clewner, Brooklyn Stack,Maria L Varela,Andrea Comba, Grace Abbud,Sebastien Motsch,Maria G Castro,Pedro R Lowenstein
Advanced science (Weinheim, Baden-Wurttemberg, Germany)no. 18 (2024): e2309796-e2309796
bioRxiv the preprint server for biology (2024)
bioRxiv : the preprint server for biology (2023)
Syed M. Faisal,Andrea Comba, Maria L. Varela,Anna E. Argento,Emily Brumley, Molly E. West, Santiago Haase,Anzar A. Mujeeb, Clifford Abel,Marcus N. Barissi, Jarred E. Clewner, Brooklyn Stack,
CANCER RESEARCHno. 7 (2023): 5835-5835
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn